Foghorn Therapeutics Inc. reported its financial results for the fiscal year ending December 31, 2025, revealing a collaboration revenue of $30.9 million, an increase from $22.6 million in 2024. This growth is attributed to the ongoing advancement of programs under its collaboration agreement with Eli Lilly and Company. Despite this revenue increase, the company continues to face significant operating losses, reporting a net loss of $74.3 million for 2025, compared to a net loss of $86.6 million in the previous year. The accumulated deficit as of December 31, 2025, stands at $632.5 million.
Operating expenses for Foghorn decreased to $117.3 million in 2025 from $125.3 million in 2024. The reduction was primarily driven by a significant decrease in research and development expenses, which fell to $85.5 million from $94.5 million, largely due to the discontinuation of the independent development of FHD-286. General and administrative expenses also saw a slight decline, totaling $27.6 million compared to $28.4 million in 2024. The company recorded a gain of $1.6 million from a lease modification and an impairment charge of $5.9 million related to long-lived assets.
Foghorn's workforce consisted of 106 employees as of December 31, 2025, with a focus on advancing its proprietary Gene Traffic Control platform, which aims to develop therapies targeting the chromatin regulatory system. The company is currently in a Phase 1 clinical trial for its lead product candidate, FHD-909, which is being developed in collaboration with Lilly. The company anticipates filing four Investigational New Drug Applications (INDs) over the next two years, reflecting its commitment to expanding its pipeline.
Looking ahead, Foghorn expects to continue incurring significant expenses as it advances its clinical programs and seeks additional funding to support its operations. The company has indicated that its cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025, will be sufficient to fund its operations for at least the next twelve months. However, it acknowledges the need for substantial additional funding to support ongoing and future clinical activities, which may include public or private equity offerings, debt financings, and collaborations. The company’s ability to achieve profitability remains uncertain, hinging on the successful development and commercialization of its product candidates.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics is a biotechnology company focused on developing precision cancer therapies by targeting the chromatin regulatory system, which controls gene expression. Using its proprietary Gene Traffic Control platform, it identifies and drug genetically defined dependencies in cancer cells. The company’s pipeline includes novel small molecule inhibitors, degraders, and disruptors, with a focus on oncology and potential applications in other diseases.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.